Aarti Drugs Lowers FY27 Volume Growth Guidance To 5-10% From 15% Amid Rising API Prices

Market snapshot: Aarti Drugs Limited has revised its FY27 volume growth expectation downward to 5–10% from the earlier forecast of 15%. Management cited customer purchasing cutbacks and deliberate avoidance of inventory stockpiling caused by elevated Active Pharmaceutical Ingredient (API) prices.

Data Snapshot

• Revised FY27 volume growth expectation lowered to 5–10% from 15%
• Q2 FY27 quarterly revenue from operations reached ₹829 crore
• Q2 FY27 net profit increased 83.2% YoY to ₹82.9 crore
• Q2 FY27 EBITDA margin expanded 370 basis points YoY to 16.6%

What's Changed

• FY27 volume growth expectations reduced by 500–1000 bps from 15% to 5–10%.
• Pharmaceutical formulator clients shifted procurement behavior toward lean, hand-to-mouth buying to avoid high inventory carry costs.

Key Takeaways

• Target recalibration: Aarti Drugs adjusted its FY27 volume growth guidance down to 5–10% as customers react to higher pricing.
• Destocking discipline: Formulators and domestic buying partners are intentionally curtailing stockpiling to manage working capital limits.
• Realisation protection: While unit volume momentum slows, higher realisations have shielded operational profitability, driving Q2 FY27 EBITDA margin up to 16.6%.

SAHI Perspective

The lowered volume target reflects a standard price-volume tradeoff in active pharmaceutical ingredients. Elevated API prices enhance top-line realizations and protect operating margins, but simultaneously temper order volumes as formulators minimize inventory risk. Investors should monitor whether raw material cost trends stabilize, allowing volume throughput to normalize over the coming quarters.

Market Implications

Near-term revenue growth for active ingredient manufacturers will depend more heavily on price realizations than unit volume expansion. Broader pharmaceutical chemical suppliers could experience similar purchasing moderation if raw material inputs stay elevated.

Trading Signals

Market Bias: Neutral

Market bias stays neutral as the reduction in FY27 volume growth guidance to 5–10% is offset by strong Q2 FY27 profitability, including an EBITDA margin expansion to 16.6% and a net profit increase of 83.2% YoY.

Overweight: Integrated API manufacturers with cost pass-through capacity

Underweight: Price-sensitive generic bulk drug segments

Trigger Factors:

• Softening or stabilization in primary API raw material costs
• Resumption of normal formulator inventory building in H2 FY27
• Export demand recovery across international formulation markets

Time Horizon: Near-term (0-3 months)

Industry Context

The active pharmaceutical ingredient sector has encountered raw material price inflation, forcing formulators to adopt tight inventory management. Backward-integrated manufacturers with downstream derivative options are better positioned to safeguard operating margins even during volume compression phases.

Key Risks to Watch

• Persistent buyer pushback on purchase volumes if raw material costs stay high
• Inability to sustain margin levels if API realisations drop faster than volume recovery
• Global freight and supply chain volatility affecting international fulfillment schedules

Recent Developments

In July 2026, Aarti Drugs announced a planned top-tier management transition, elevating Shri Rashesh C. Gogri to Chairman & Managing Director and Shri Adhish P. Patil to Managing Director, effective October 1, 2026. On November 3, 2026, the company reported Q2 FY27 results featuring quarterly revenue of ₹829 crore and net profit of ₹82.9 crore.

Closing Insight

Aarti Drugs' guidance adjustment signals that formulators are prioritizing working capital management over inventory accumulation, directing focus toward margin preservation while volume growth temporarily moderates.

High Performance Trading with SAHI.